



## Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma (HCC): What's New for This Old Treatment?

Guest Editor:

**Prof. Thomas Decaens**

Service d'Hépatologie  
Gastroentérologie et d'Oncologie  
Digestive, CHU Grenoble-Alpes,  
Grenoble 38043, France.  
Université Grenoble Alpes, 38000  
Grenoble, France.  
Institute for Advanced  
Biosciences, Research Center  
Inserm U 1209 / CNRS 5309,  
38700 La Tronche, France.

Deadline for manuscript  
submissions:

**closed (31 August 2021)**

### Message from the Guest Editor

Dear Colleagues,

Transarterial chemoembolization has been used for many years for the treatment of hepatocellular carcinoma and it is one of the most used treatments in the world. Recent worldwide data show that TACE is associated with 40% of objective response after the first cure including 14% of complete response.

However, there is a lack of strong scientific evidence for efficacy and safety due to lack of large recent randomized control trials. There is still a debate on the real place of TACE in the HCC treatment arsenal. Immunotherapy in HCC opens new ways and opportunities.

This Special Issue will highlight the place of TACE in this new area.

Prof. Thomas Decaens  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)